About
Dr. Wiese received a BS from University of Tennessee at Chattanooga and a PhD from Vanderbilt University in Nashville Tennessee. Her dissertation research evaluated the role of microRNAs in regulating endothelial cell dysfunction within chronic kidney disease associated atherosclerosis. She joined the Reue Lab in 2019 for her postdoctoral training. Her research focuses on elucidating how X chromosome gene dosage contributes to metabolic disease sex differences.
Education and Degree(s)
- BS – Molecular Biology, University of Tennessee at Chattanooga
- PhD – Molecular Physiology & Biophysics, Vanderbilt University
Publications
For complete list of publications, please visit Pubmed.
- X chromosome dosage drives statin-induced dysglycemia and mitochondrial dysfunction.
Zhang P, Munier JJ, Wiese CB, Vergnes L, Link J, Abbasi F, Ronquillo E, Scheker K, Munoz A, Kuang Y, Theusch E, Liu M, Sanchez G, Oni-Orisan A, Iribarren C, McPhaul MJ, Nomura DK, Knowles JW, Krauss RM, Medina MW, Reue K. (2024) Nature Commun. Jul 2;15(1):5571. - Gene Regulation and Mitochondrial Activity During White and Brown Adipogenesis Are Modulated by KDM5 Histone Demethylase.
Vergnes L, Wiese CB, Zore T, Riestenberg C, Avetisyan R, Reue K. (2024) J Endocr Soc. 8(4):bvae029. - The impact of chromosomal sex on cardiometabolic health and disease.
Wiese CB, Avetisyan R, Reue K. (2023) Trends Endocrinol Metab 34:652–665. - Chromosomal and gonadal sex drive sex differences in lipids and hepatic gene expression in response to hypercholesterolemia and statin treatment.
Wiese CB, Agle ZW, Zhang P, Reue K. (2022) Biol Sex Differ 13:63. - Illuminating the mechanisms underlying sex differences in cardiovascular disease.
Reue K and Wiese CB. (2022) Circ Res 130:1747–1762. - X chromosome dosage of histone demethylase KDM5C determines sex differences in adiposity.
Link JC*, Wiese CB*, Chen X, Avetisyan R, Ronquillo E, Ma F, Guo X, Yao J, Allison M, Chen YI, Rotter JI, El-Sayed Moustafa JS, Small KS, Iwase S, Pellegrini M, Vergnes L, Arnold AP, Reue K. (2020) J Clin Invest 130:5688–5702.